Cost-effectiveness of immune checkpoint inhibitors in nsclc according to pd-l1 expression

Date
2016
Author
Aguiar, Pedro, Jr. [UNIFESP]
Perry, Luke A.
Lopes, Gilberto L., Jr.
Type
Editorial
ISSN
1758-1966
Is part of
Lung Cancer Management
DOI
10.2217/lmt-2016-0016
Metadata
Show full item record
Citation
Lung Cancer Management. London, v. 5, n. 3, p. 119-122, 2016.
Keywords
Cost-Effectiveness
Health Technology Assessment
Immunotherapy
Lung CancerCell Lung-Cancer
Predictive Biomarker
Metaanalysis
Nivolumab
Docetaxel
Outcomes
URI
http://repositorio.unifesp.br/handle/11600/49320
Collections